|  |
| --- |
| Supplementary Table 1. Diagnosis Codes for Opioid use disorder and Comorbidities |
| Diagnosis | ICD-9/-10-CM diagnosis codes |
| Opioid use disorder | 305.5, 304.0, 304.7 |
| F11 |
| Other substance use disorder | 305.0, 303, 305.4, 304.1, 305.6, 304.2, 305.2, 304.3, 305.7, 304.4, 305.3, 305.9, 304.5, 304.6, 304.8, 304.9 |
| F10, F13, F14, F12, F15, F16, F18, F19 |
| Psychiatric comorbidity | 295, 297, 298, 296, 300.4, 311, 300.0, 300.2, 300.3, 308, 309.81, 299, 315, 317, 318, 319, 300.8, 300.1, 300.5, 300.6, 300.7, 307.8, 300.9, 302.7, 307.0, 307.3, 307.4, 307.9, 309.0, 309.1, 309.2, 309.3, 309.4, 309.82, 309.83, 309.89, 309.9, 302, 312.3, 302.1, 302.2, 302.3, 302.4, 302.5, 302.6, 302.8, 302.9, 301, 307.1, 307.50, 307.51, 307.52, 307.54, 307.59, 312.0, 312.4, 312.1, 312.2, 312.81, 312.82, 312.89, 312.9, 313.81, 314, 307.2, 307.52, 307.6, 307.7, 313.0, 313.1, 313.2, 313.3, 313.8, 313.82, 313.83, 313.89, 313.9F20, F21, F22, F23, F24, F25, F28, F29, F30, F53, F40, F41, F42, F44, F45, F50, F51, F52, F55, F59, F60, F63, F64, F65, F66, F68, F69, F70, F80, F90, F91, F93, F94, F95, F98, F99, F430, F431, F432, F438, F439, F481, F482, F489 |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Supplementary Table 2. Procedural Codes for Opioid Use Disorder Treatment Services

|  |  |
| --- | --- |
| HCPCS codes | H0001 H0002 H0003 H0004 H0005 H0006 H0007 H0008 H0009 H0010 H0011 H0012 H0013 H0014 H0015 H0016 H0017 H0018 H0019 H0020 H0021 H0022 H0023 H0024 H0025 H0026 H0027 H0028 H0029 H0030 H0031 H0032 H0033 H0034 H0035 H0036 H0037 H0038 H0039 H0040 H0041 H0042 H0043 H0044 H0045 H0046 H0047 H0048 H0049 H0050 H1000 H1001 H1002 H1003 H1004 H1005 H1010 H1011 H2000 H2001 H2010 H2011 H2012 H2013 H2014 H2015 H2016 H2017 H2018 H2019 H20201 H2021 H2022 H2023 H2024 H2025 H2026 H2027 H2028 H2029 H2030 H2031 H2032 H2033 H2034 H2035 H2036 H2037 J23152 T1002 T1006 T1007 T1012 T1016 T2048  |
| CPT codes | 90791 90832 90834 90837 90840 90845 90846 90847 90849 90853 90839 90801 90802 90804 90806 90808 90810 90812 90814 90816 90818 90821 90823 90826 90828 90857 |
| ICD-9/ICD-10 Codes | 9464 94653 9466 9467 94684 9469HZ2ZZZZ5 HZ30ZZZ HZ31ZZZ HZ32ZZZ HZ33ZZZ HZ34ZZZ HZ35ZZZ HZ36ZZZ HZ37ZZZ HZ38ZZZ HZ39ZZZ HZ3BZZZ HZ40ZZZ HZ41ZZZ HZ42ZZZ HZ43ZZZ HZ44ZZZ HZ45ZZZ HZ46ZZZ HZ47ZZZ HZ48ZZZ HZ49ZZZ HZ4BZZZ |

HCPCS= Healthcare Common Procedure Coding System; CPT= Current Procedural Terminology; ICD= International Statistical Classification of Diseases. 1Denotes methadone administration. 2Denotes extended-release naltrexone administration. 3-5Denotes detoxification services. Services without footnotes indicate psychosocial treatment.Supplementary Table 3. National Drug Codes Used to Identify Pharmacy Claims for Opioid Use Disorder Medications |
| Medication | National Drug Codes |
| Buprenorphine | 00054017613 00054017713 00054018813 00054018913 00093537856 00093537956 00093572056 00093572156 00228315303 00228315403 00228315473 00228315503 00228315573 00228315603 00378092393 00378092493 00406192303 00406192403 00490005130 12496120201 12496120203 12496120401 12496120403 12496120801 12496120803 12496121201 12496121203 12496127802 12496128302 12496130602 12496131002 16590066630 16590066730 23490927003 35356000430 38779088800 38779088801 38779088803 38779088809 42291017430 42291017530 43063018430 49452129203 49452825301 49452825302 49452825303 49452825304 49999039515 49999063830 49999063930 50383028793 50383029493 50383092493 50383093093 51927101200 52959030430 52959074930 54123011430 54123091430 54123092930 54123095730 54123098630 54569573900 54569573901 54569573902 54569639900 54868570700 54868570701 54868575000 55700014730 59385001201 59385001230 59385001401 59385001430 59385001601 59385001630 60429058630 60429058730 62991158301 62991158302 62991158303 62991158304 63275992202 63370090506 63370090509 63370090510 63370090515 63874108503 63874117303 65162041503 65162041603 68071151003 68308020830 |
| Naltrexone (oral) | 00056001130 00056001170 00185003901 00185003930 00406117001 00406117003 00555090201 00555090202 16729008101 16729008110 38779088703 38779088704 38779088705 38779088706 42291063230 47335032683 47335032688 49452483501 49452483502 51224020630 51224020650 51285027501 51285027502 51552073701 51552073702 51927354800 51927360200 51927437700 52152010502 52152010530 52372075102 62991124301 62991124302 62991124303 62991124304 63370015810 63370015815 63370015825 63370015835 68084029121 68094085362 |
| Extended-release Naltrexone | 63459030042 65757030001  |

Supplementary Table 4. Regression outputs for models predicting prevalence of six-month treatment retention, stratified by treatment type.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Combined Treatment Groups | Psychosocial Only | Naltrexone (XR or oral) | Buprenorphine |
|  | *n*=261,356 | *n*=120,475 | *n*=15,489 | *n*=125,392 |
|  | AOR (95% CI) | AOR (95% CI) | AOR (95% CI) | AOR (95% CI) |
| Age Group |  |  |  |  |
|  12-17 | 0.43 (0.40, 0.46)\*\*\* | 0.86 (0.77, 0.96)\*\*\* | 2.02 (1.61, 2.55)\*\*\* | 0.69 (0.60, 0.81)\*\*\* |
|  18-25 | 0.67 (0.66, 0.69)\*\*\* | 0.79 (0.76, 0.82)\*\* | 0.94 (0.86, 1.03) | 0.68 (0.66, 0.70)\*\*\* |
|  26-64 | Ref | Ref | Ref | Ref |
| Sex |  |  |  |  |
|  Female | 1.07 (1.05, 1.09)\*\*\* | 1.24 (1.20, 1.29)\*\*\* | 1.03 (0.95, 1.13) | 1.02 (0.99, 1.04) |
|  Male  | Ref | Ref | Ref | Ref |
| Co-morbid SUD |  |  |  |  |
|  Yes | 0.63 (0.62, 0.64)\*\*\* | 0.79 (0.76, 0.81)\*\*\* | 0.95 (0.87, 1.03) | 0.87 (0.85, 0.89)\*\*\* |
|  No | Ref | Ref | Ref | Ref |
| Co-morbid Psychiatric disorder |  |  |  |  |
|  Yes | 0.91 (0.89, 0.93)\*\*\* | 0.93 (0.90, 0.96)\*\*\* | 1.01 (0.92, 1.11) | 1.01 (0.98, 1.03) |
|  No | Ref | Ref | Ref | Ref |
| Previous OUD diagnosis |  |  |  |  |
|  Yes | 1.04 (1.03, 1.06)\*\*\* | 1.12 (1.08, 1.15)\*\*\* | 1.03 (0.94, 1.12) | 0.97 (0.95, 0.99)\* |
|  No | Ref | Ref | Ref | Ref |
| Year\*Insurance Status |  |  |  |  |
|  2016\*Commercial | 1.31 (1.18, 1.46)\*\*\* | 1.32 (0.97, 1.81) | 1.78 (1.09, 2.91)\* | 1.36 (1.19, 1.55)\*\*\* |
|  2016\*Medicaid | 0.89 (0.80, 0.99)\* | 2.77 (2.08, 3.69)\*\*\* | 3.45 (2.10, 5.64)\*\*\* | 1.20 (1.05, 1.36)\*\* |
|  2015\*Commercial | 1.26 (1.13, 1.40)\*\*\* | 1.40 (1.04, 1.89)\* | 1.59 (0.98, 2.58) | 1.26 (1.11, 1.42)\*\*\* |
|  2015\*Medicaid | 0.78 (0.70, 0.86)\*\*\* | 2.95 (2.22, 3.93)\*\*\* | 3.29 (2.02, 5.37)\*\*\* | 0.63 (0.55, 0.71)\*\*\* |
|  2014\*Commercial | 1.31 (1.18, 1.46)\*\*\* | 1.28 (0.95, 1.73) | 1.42 (0.87, 2.30) | 1.30 (1.15, 1.48)\*\*\* |
|  2014\*Medicaid | 0.87 (0.78, 0.96)\*\* | 2.74 (2.06, 3.65)\*\*\* | 2.64 (1.59, 4.40)\*\*\* | 1.01 (0.88, 1.15) |
|  2013\*Commercial | 1.29 (1.16, 1.43)\*\*\* | 1.09 (0.81, 1.47) | 1.29 (0.79, 2.11) | 1.18 (1.04, 1.34)\*\* |
|  2013\*Medicaid | 0.85 (0.77, 0.95)\*\* | 2.57 (1.93, 3.43)\*\*\* | 1.56 (0.91, 2.67) | 0.89 (0.79, 1.02) |
|  2012\*Commercial | 1.34 (1.21, 1.48)\*\*\* | 0.93 (0.69, 1.26) | 1.39 (0.85, 2.27) | 1.22 (1.08, 1.38)\*\* |
|  2012\*Medicaid | 0.85 (0.76, 0.94)\*\* | 2.17 (1.62, 2.90)\*\*\* | 1.42 (0.82, 2.46) | 1.10 (0.96, 1.26) |
|  2011\*Commercial | 1.32 (1.19, 1.46)\*\*\* | 0.88 (0.65, 1.19) | 1.20 (0.73, 1.98) | 1.16 (1.03, 1.32)\* |
|  2011\*Medicaid | 0.98 (0.86, 1.11) | 0.94 (0.67, 1.32) | 1.42 (0.73, 2.77) | 1.59 (1.36, 1.87)\*\*\* |
|  2010\*Commercial | 1.32 (1.19, 1.46)\*\*\* | 0.82 (0.60, 1.13) | 1.23 (0.73, 2.05) | 1.11 (0.98, 1.26) |
|  2009\*Commercial | 1.37 (1.23, 1.52)\*\*\* | 0.83 (0.61, 1.14) | 1.32 (0.79, 2.22) | 1.18 (1.04, 1.33)\* |
|  2008\*Commercial | 1.38 (1.24, 1.54)\*\*\* | 0.82 (0.59, 1.14) | 1.03 (0.60, 1.77) | 1.21 (1.06, 1.37)\*\* |
|  2007\*Commercial | 1.24 (1.10, 1.38)\*\*\* | 1.10 (0.79, 1.54) | 0.74 (0.41, 1.33) | 1.13 (0.99, 1.29) |
|  2006\*Commercial | Ref | Ref | Ref | Ref |

AOR= Adjusted odds ratio. CI= confidence interval. XR= Extended release. SUD= substance use disorder. OUD=opioid use disorder. \**p*<.05, \*\**p*<.01, \*\*\**p*<.001.

Supplementary Table 5. Regression outputs for models predicting prevalence of six-month treatment retention, stratified by age group.

|  |  |  |  |
| --- | --- | --- | --- |
|  | 12-17 | 18-25 | 26-64 |
|  | *n*=4,979 | *n*=76,229 | *n*=180,148 |
|  | AOR (95% CI) | AOR (95% CI) | AOR (95% CI) |
| Treatment Type |  |  |  |
|  Buprenorphine | 7.52 (6.08, 9.31)\*\*\* | 5.9 (5.65, 6.16)\*\*\* | 4.38 (4.27, 4.49)\*\*\* |
|  Naltrexone (oral or XR) | 4.31 (3.35, 5.54)\*\*\* | 2.02 (1.87, 2.19)\*\*\* | 1.24 (1.17, 1.31)\*\*\* |
|  Psychosocial Services Only | Ref | Ref | Ref |
| Sex |  |  |  |
|  Female | 0.96 (0.82, 1.16) | 1.03 (1.00, 1.07) | 1.07 (1.05, 1.10)\*\*\* |
|  Male | Ref | Ref | Ref |
| Co-morbid SUD |  |  |  |
|  Yes | 0.98 (0.82, 1.16) | 0.81 (0.78, 0.84)\*\*\* | 0.84 (0.82, 0.86)\*\*\* |
|  No | Ref | Ref | Ref |
| Psychiatric co-morbidity |  |  |  |
|  Yes | 1.11 (0.91, 1.34) | 1.01 (0.98, 1.05) | 0.95 (0.92, 0.97)\*\*\* |
|  No | Ref | Ref | Ref |
| Previous OUD diagnosis |  |  |  |
|  Yes | 1.12 (0.94, 1.33) | 1.03 (0.99, 1.06) | 1.04 (1.01, 1.06)\*\* |
|  No | Ref | Ref | Ref |
| Year\*Insurance Status |  |  |  |
|  2016\*Commercial | 1.18 (0.40, 3.48) | 1.25 (0.99, 1.59) | 1.43 (1.26, 1.63)\*\*\* |
|  2016\*Medicaid | 3.07 (1.20, 7.82)\* | 2.01 (1.58, 2.55)\*\*\* | 1.53 (1.36,1.73)\*\*\* |
|  2015\*Commercial | 1.67 (0.65, 4.29) | 1.17 (0.93, 1.46) | 1.37 (1.21, 1.55)\*\*\* |
|  2015\*Medicaid | 2.89 (1.17, 7.12)\* | 2.00 (1.59, 2.53)\*\*\* | 1.27 (1.13, 1.43)\*\*\* |
|  2014\*Commercial | 1.93 (0.77, 4.86) | 1.21 (0.97, 1.52) | 1.37 (1.21, 1.54)\*\*\* |
|  2014\*Medicaid | 2.71 (1.10, 6.72)\* | 2.12 (1.67, 2.68)\*\*\* | 1.37 (1.22, 1.55)\*\*\* |
|  2013\*Commercial | 2.85 (1.16, 6.97)\* | 1.08 (0.86, 1.36) | 1.27 (1.12, 1.43)\*\*\* |
|  2013\*Medicaid | 4.38 (1.78, 10.77)\*\* | 1.77 (1.40, 2.25)\*\*\* | 1.19 (1.05, 1.34)\*\* |
|  2012\*Commercial | 1.45 (0.59, 3.53) | 1.19 (0.95, 1.49) | 1.24 (1.10, 1.40)\*\*\* |
|  2012\*Medicaid | 3.09 (1.25, 7.64)\* | 1.64 (1.29, 2.09)\*\*\* | 1.22 (1.08, 1.38)\*\* |
|  2011\*Commercial | 1.67 (0.69, 4.05) | 1.15 (0.92, 1.45) | 1.17 (1.04, 1.32)\* |
|  2011\*Medicaid | 1.79 (0.64, 5.03) | 1.40 (1.05, 1.86)\* | 1.18 (1.02, 1.36)\* |
|  2010\*Commercial | 1.35 (0.55, 3.29) | 1.19 (0.95, 1.50) | 1.11 (0.98, 1.25) |
|  2009\*Commercial | 1.47 (0.61, 3.56) | 1.28 (1.01, 1.61)\* | 1.16 (1.02, 1.31)\* |
|  2008\*Commercial | 1.34 (0.54, 3.29) | 1.23 (0.97, 1.56) | 1.20 (1.06, 1.35)\*\* |
|  2007\*Commercial | 1.36 (0.55, 3.35) | 1.27 (0.99, 1.63) | 1.09 (0.96, 1.24) |
|  2006\*Commercial | Ref | Ref | Ref |

AOR= Adjusted odds ratio. CI= confidence interval. XR= Extended release. SUD= substance use disorder. OUD=opioid use disorder. \**p*<.05, \*\**p*<.01, \*\*\**p*<.001.

Supplementary Table 6. Association between age group and 90-day treatment retention, stratified by treatment type.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Combined Treatment Groups | Psychosocial Services Only | Naltrexone (oral or XR) | Buprenorphine |
|  | *n*=304,748 | *n*=142,378 | *n*=18,561 | *n*=143,809 |
|  | Adjusted Prevalence(95% CI) | AOR (95% CI) | Adjusted Prevalence(95% CI) | AOR (95% CI) | Adjusted Prevalence(95% CI) | AOR (95% CI) | Adjusted Prevalence(95% CI) | AOR (95% CI) |
| Age Group |
|  12-17  | 36.76 (35.43, 38.11) | 0.63 (0.60, 0.67)\*\*\* | 34.19 (32.62, 35.79) | 1.12 (1.04, 1.20)\*\* | 59.81 (55.00, 64.44) | 2.35 (1.92, 2.87)\*\*\* | 59.53 (56.03, 62.93) | 0.88 (0.77, 1.02) |
|  18-25 | 41.25 (40.90, 41.60) | 0.76 (0.75, 0.78)\*\*\* | 28.94 (28.45, 29.44) | 0.88 (0.85, 0.90)\*\*\* | 38.21 (36.97, 39.48) | 0.98 (0.91, 1.05) | 56.02 (55.51, 56.53) | 0.77 (0.75, 0.79)\*\*\* |
|  26-64 | 47.88 (47.65, 48.12) | 1.00 (Ref) | 31.70 (31.39, 32.02) | 1.00 (Ref) | 38.77 (37.81, 39.74) | 1.00 (Ref) | 62.47 (62.12, 62.83) | 1.00 (Ref) |

AOR= adjusted odds ratio. CI= confidence interval. XR= extended release. \*\**p*<.01, \*\*\**p*<.001. All models adjusted for sex, co-morbid substance use disorder, co-morbid psychiatric disorder, previous diagnosis of opioid use disorder, insurance status and year.

Supplementary Table 7. Association between treatment type and 90-day retention, stratified by age group.

|  |  |  |  |
| --- | --- | --- | --- |
|  | 12-17 | 18-25 | 26-64 |
|  | *n*=5,499 | *n*=89,397 | *n*=209,852 |
|  | Adjusted Prevalence (95% CI) | AOR (95% CI) | Adjusted Prevalence (95% CI) | AOR (95% CI) | Adjusted Prevalence (95% CI) | AOR (95% CI) |
| Treatment Type |  |  |  |  |  |  |
|  Buprenorphine | 65.10 (61.39, 68.64) | 5.01 (4.35, 6.26)\*\*\* | 57.88 (57.35, 58.40) | 4.22 (4.08, 4.37)\*\*\* | 63.12 (62.76, 63.49) | 3.46 (3.38, 3.54)\*\*\* |
|  Naltrexone (XR or oral) | 58.80 (53.91, 63.52) | 3.99 (3.26, 4.94)\*\*\* | 39.81 (38.58, 41.06) | 2.03 (1.92, 2.15)\*\*\* | 41.22 (40.25, 42.19) | 1.42 (1.36, 1.48)\*\*\* |
|  Psychosocial services only | 26.33 (24.96, 27.75) | 1.00 (Ref) | 24.57 (24.12, 25.02) | 1.00 (Ref) | 33.09 (32.77, 33.42) | 1.00 (Ref) |

AOR= adjusted odds ratio. CI= confidence interval. XR= extended release. \*\**p*<.01, \*\*\**p*<.001. All models adjusted for sex, co-morbid substance use disorder, co-morbid psychiatric disorder, previous diagnosis of opioid use disorder, insurance status and year.

Supplementary Table 8. Association between age group and six-month treatment retention stratified by treatment type and co-morbidity severity.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Combined Treatment Groups | Psychosocial Only | Naltrexone (XR and oral) | Buprenorphine |
|  | Low co-morbidity | High co-morbidity | Low co-morbidity | High co-morbidity | Low co-morbidity | High co-morbidity | Low co-morbidity | High co-morbidity |
|  | *n*=147,731 | *n*=113,625 | *n*=56,707 | *n*=63,768 | *n*=5,475 | *n*=10,014 | *n*=85,549 | *n*=39,843 |
|  | AOR (95% CI) | AOR (95% CI) | AOR (95% CI) | AOR (95% CI) | AOR (95% CI) | AOR (95% CI) | AOR (95% CI) | AOR (95% CI) |
|  |  |  |  |  |  |  |  |  |
| Age Group |  |  |  |  |  |  |  |
|  12-17 | 0.33 (0.29, 0.38)\*\*\* | 0.53 (0.48, 0.58)\*\*\* | 0.73 (0.59, 0.89)\*\* | 0.95 (0.83, 1.07) | 1.78 (1.00, 3.17) | 2.07 (1.61, 2.66)\*\*\* | 0.58 (0.47, 0.72)\*\*\* | 0.84 (0.68, 1.04) |
|  18-25 | 0.64 (0.62, 0.66)\*\*\* | 0.75 (0.72, 0.77)\*\*\* | 0.76 (0.71, 0.80)\*\*\* | 0.83 (0.78, 0.88)\*\*\* | 0.89 (0.76, 1.04) | 0.96 (0.85, 1.07) | 0.68 (0.66, 0.71)\*\*\* | 0.68 (0.65, 0.72)\*\*\* |
|  26-64 | 1.00 (Ref) | 1.00 (Ref) | 1.00 (Ref) | 1.00 (Ref) | 1.00 (Ref) | 1.00 (Ref) | 1.00 (Ref) | 1.00 (Ref) |

AOR= adjusted odds ratio. CI= confidence interval. XR= extended release. \**p*<.05, \*\**p*<.01, \*\*\**p*<.001. All models adjusted for sex, co-morbid substance use disorder, co-morbid psychiatric disorder, previous diagnosis of opioid use disorder, insurance status and year.

Supplementary Table 9. Association between treatment type and six-month treatment retention, stratified by age group and co-morbidity severity.

|  |  |  |  |
| --- | --- | --- | --- |
|  | 12-17 | 18-25 | 26-64 |
|  | Low co-morbidity | High co-morbidity | Low co-morbidity | High co-morbidity | Low co-morbidity | High co-morbidity |
|  | *n*=1,541 | *n*=3,438 | *n*=42,255 | *n*=33,974 | *n*=103,935 | *n*=76,213 |
|  | AOR (95% CI) | AOR (95% CI) | AOR (95% CI) | AOR (95% CI) | AOR (95% CI) | AOR (95% CI) |
| Treatment Type |  |  |  |  |  |  |
|  Buprenorphine | 6.19 (4.47, 8.58)\*\*\* | 8.85 (6.66, 11.76)\*\*\* | 5.67 (5.35, 6.00)\*\*\* | 6.14 (5.76, 6.55)\*\*\* | 3.95 (3.82, 4.09)\*\*\* | 4.90 (4.71, 5.09)\*\*\* |
|  Naltrexone (XR or oral) | 3.45 (1.91, 6.23)\*\* | 4.63 (3.49, 6.13)\*\*\* | 1.65 (1.45, 1.88)\*\*\* | 2.33 (2.10, 2.58)\*\*\* | 1.01 (0.92, 1.10) | 1.49 (1.39, 1.60)\*\*\* |
|  Psychosocial only | 1.00 (Ref) | 1.00 (Ref) | 1.00 (Ref) | 1.00 (Ref) | 1.00 (Ref) | 1.00 (Ref) |

AOR= adjusted odds ratio. CI= confidence interval. XR= extended release. \**p*<.05, \*\**p*<.01, \*\*\**p*<.001. All models adjusted for sex, co-morbid substance use disorder, co-morbid psychiatric disorder, previous diagnosis of opioid use disorder, insurance status and year.